TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Gain Therapeutics ( (GANX) ).
Gain Therapeutics, Inc., a company involved in the sale of common stock, announced on November 28, 2025, that it has filed a prospectus supplement with the SEC for an ‘at the market offering’ program. This program allows the company to offer and sell up to $35,530,980.56 of its common stock through Oppenheimer & Co. Inc. as the sales agent. As of the announcement, the company has already sold $14,469,019.44 worth of stock under the existing Equity Distribution Agreement. The legal opinion regarding the validity of this stock offering has been provided by Lowenstein Sandler LLP.
The most recent analyst rating on (GANX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.
Spark’s Take on GANX Stock
According to Spark, TipRanks’ AI Analyst, GANX is a Neutral.
Gain Therapeutics is currently challenged by significant financial difficulties, with no revenue growth and persistent losses impacting profitability. These weaknesses heavily weigh down the stock score. Despite these challenges, technical analysis shows mixed signals, and recent positive corporate events related to Parkinson’s treatment offer some hope for future prospects. However, the negative valuation metrics further underscore the risks, leading to an overall cautious outlook.
To see Spark’s full report on GANX stock, click here.
More about Gain Therapeutics
Average Trading Volume: 926,659
Technical Sentiment Signal: Buy
Current Market Cap: $113.3M
For an in-depth examination of GANX stock, go to TipRanks’ Overview page.